Overview

Study to Evaluate the Safety and Efficacy of Levetiracetam in Patients Suffering From Idiopathic Generalized Epilepsy With Primary Generalized Tonic-clonic Seizures

Status:
Completed

Trial end date:
2005-06-01

Target enrollment:

Participant gender:

Summary

This study will assess the efficacy, safety, and tolerability of adjunctive treatment with LEV (3,000 mg/day or a target dose of 60 mg/kg/day in children) compared to placebo in reducing PGTC seizures in subjects (4 - 65 years) suffering from idiopathic generalized epilepsy uncontrolled despite treatment with one or two concomitant AEDs.

Phase:

Phase 3

Details

Lead Sponsor:

UCB Pharma

Treatments:

Etiracetam
Levetiracetam
Piracetam